GMO International Equity Fund Class IV (GMCFX) Annual Shareholder Report - February 28, 2025

GMO

This annual shareholder report contains important information about GMO International Equity Fund for the period of March 1, 2024 to February 28, 2025. You can find additional information about the Fund at https://www.gmo.com/americas/mutual-fund-documents/. You can also request this information by contacting us at (617) 346-7646 (collect).

What were the Fund costs for the last year?

(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Class IV	\$198	1.81%1

¹ Includes non-recurring legal fees from a one-time litigation settlement which increased the hypothetical expense ratio above by 1.20%.

How did the Fund perform last year and what affected its performance?

Although the Fund is not managed relative to any securities market index or benchmark, a discussion of the Fund's performance relative to the MSCI EAFE Index is included for comparative purposes.

Class IV shares of GMO International Equity Fund returned +18.85% (net) for the fiscal year ended February 28, 2025, as compared with +8.77% for the MSCI EAFE Index.

Strong stock selection, country allocation, and sector allocation all contributed to portfolio outperformance relative to its benchmark. Financials delivered notable contributions from overweight positioning toward Spanish and Italian Financials. Other areas of positive stock selection included Health Care, Consumer Staples, Information Technology, Consumer Discretionary, the Netherlands, and Japan.


Decisions which detracted from performance included stock selection in Industrials, and a mix of overweight positioning and stock selection in French Information Technology and Italian Consumer Discretionary.

Returns include a substantial, one-time litigation settlement recovery received on December 16, 2024. This event contributed 5.52% to the performance for the fiscal year ended February 28, 2025. Performance for other periods including this date was also positively impacted, sometimes materially. Without this recovery, performance would have been lower in both absolute terms and relative to the benchmark. Additional information is available upon request.

The views expressed herein are exclusively those of Grantham, Mayo, Van Otterloo & Co. LLC as of the date of this report and are subject to change. GMO disclaims any responsibility to update such views. They are not meant as investment advice. References to specific securities are not recommendations of such securities and may not be representative of any GMO portfolio's current or future investments.

Fund Performance

Change in Value of a \$125,000,000 Investment



Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. To obtain performance information up to the most recent month-end, visit www.gmo.com. Performance shown is net of all fees after reimbursement from GMO. Returns would have been lower had certain expenses not been reimbursed during the periods shown and do not include the effect of taxes on distributions and redemptions. The performance information shown above only includes purchase premiums and/or redemption fees in effect as of February 28, 2025.

*Returns include a substantial, one-time litigation settlement recovery received on December 16, 2024. This event contributed 5.52% to the performance for the fiscal year ended February 28, 2025. Performance for other periods including this date was also positively impacted, sometimes materially. Without this recovery, performance would have been lower in both absolute terms and relative to the benchmark. Additional information is available upon request.

MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

The gross expense ratio of 0.66% for Class IV is equal to the Total Annual Operating Expenses set forth in the Fund's most recent prospectus dated June 30, 2024. The net expense ratio of 0.62% reflects the reduction of expenses from fee reimbursements. The fee reimbursements will continue until at least June 30, 2025 and may not be terminated prior to this date without the action or consent of the Trust's Board of Trustees. Elimination of this reimbursement will result in higher fees and lower performance.

Key Fund Statistics Total Net Assets	\$1,017,658,647
Number of Portfolio Holdings	193
Portfolio Turnover Rate	71%*
Total Advisory Fees Paid, Net	\$4,906,163

The portfolio turnover rate excludes investments in GMO U.S. Treasury Fund ("USTF") which is used as a short-term investment vehicle for cash management. The portfolio turnover rate including transactions in USTF during the period was 84%.

What does the Fund invest in? The Fund primarily invested in equity securities at year end.

Country/Region Summary*	% of Investments	Industry Group Summary**	% of Investments
Japan	23.8	Banks	11.4
United Kingdom	12.5	Capital Goods	11.0
France	10.0	Pharmaceuticals, Biotechnology & Life Sciences	9.0
Netherlands	7.9	Insurance	8.2
Germany	7.4	Financial Services	7.7
Spain	6.4	Consumer Durables & Apparel	6.3
Switzerland	6.2	Software & Services	6.2
United States	5.0	Technology Hardware & Equipment	6.1
Singapore	4.8	Telecommunication Services	5.9
Italy	4.6	Consumer Discretionary Distribution & Retail	5.5
Australia	3.0	Food, Beverage & Tobacco	5.3
Hong Kong	2.4	Commercial & Professional Services	4.7
Finland	2.0	Consumer Staples Distribution & Retail	3.0
Belgium	1.5	Materials	2.4
Other (each less than 1%)	2.5	Automobiles & Components	2.2
		Media & Entertainment	2.0
		Other (each less than 1%)	3.1

- Excludes short-term investments and derivative financial instruments, if any.
- ** Excludes short-term investments, mutual funds and derivative financial instruments, if any.

Additional Information

For additional information about the Fund, including the Fund's prospectus, financial statements, quarterly portfolio holdings and proxy voting information, please visit https://www.gmo.com/americas/mutual-fund-documents/ or scan the QR code.

